Potential Cancer Breakthrough: Groundbreaking New Report Shows 84% Clinical Benefit Ratio for Ivermectin+Mebendazole in Cancer Care
A new observational report from The Wellness Company highlights promising real-world outcomes using ivermectin and mebendazole in cancer patients, with an 84% clinical benefit rate and nearly half of participants reporting tumor reduction or no evidence of disease. While early and still under peer review, the findings point to the potential of repurposed, well-tolerated medications as a complementary approach in cancer care—warranting further rigorous clinical investigation.
Read More
